Cancer Research Technology Ltd. operates as a pharmaceutical research and development company. The Company researches, develops, markets, and commercializes cancer therapeutics, and vaccines, Cancer Research offers its services and products to cancer charity organizations throughout the United Kingdom.
In India, the Pharmaceutical business of Cancer Research Technology Ltd is focused on Therapeutic agents, Azaquinazoline inhibitors of atypical protein kinase C, N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors, N2-phenyl-pyrido[3,4-D]pyrimidine-2, 8-diamine derivatives and their use as Mps1 inhibitors.
Cancer Research Technology Limited filed patent application numbered 45/MUMNP/2015 that is titled A COMPOUND OF FORMULA (I). This Patent Application has been granted as as Patent number 317047.
The invention covers chemical compound. The invention relates to compounds of formula I: wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The compounds of formula I are inhibitors of aurora kinase and/or FLT3. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which aurora kinase and/or FLT3 activity is implicated.
During patent examination, the patent examiner raised objections under Section 3(d) and said that claim 1-10 falls within 3(d).
As a response to the said objection, the applicant submitted that the claimed compounds are not derivatives of a known compound, but are new and non-obvious compounds not taught or suggested in the references. Claimed compounds differ significantly in their structure compared to those compounds. Certainly, the claimed compounds could not be “derived” by chemically modifying the prior art compounds. The product is safe and have good therapeutic index. It is more effective drug.
Advocate Rahul Dev is a Patent Attorney & International Business Lawyer practicing Technology, Intellectual Property & Corporate Laws. He is reachable at rd (at) patentbusinesslawyer (dot) com & @rdpatentlawyer on Twitter.
Quoted in and contributed to 50+ national & international publications (Bloomberg, FirstPost, SwissInfo, Outlook Money, Yahoo News, Times of India, Economic Times, Business Standard, Quartz, Global Legal Post, International Bar Association, LawAsia, BioSpectrum Asia, Digital News Asia, e27, Leaders Speak, Entrepreneur India, VCCircle, AutoTech).
Regularly invited to speak at international & national platforms (conferences, TV channels, seminars, corporate trainings, government workshops) on technology, patents, business strategy, legal developments, leadership & management.
